French department store Printemps brings surprisingly thrilling food to Wall Street
They're at Printemps, the new Paris-based fashion store that's the glam showpiece of One Wall Street — the landmarked former Irving Trust office building recently converted to luxury condos.
The neighborhood, once starved for quality cuisine, is now a lively residential district as well as a business hub.
7 Printemps opened in the Financial District in March, bringing French fashions —and five restaurants — to the neighborhood.
Brian Zak/NY Post
It's enjoying a dining renaissance with the revived Delmonico's on Beaver Street, SAGA and Crown Shy at 70 Pine Street and lively indoor-outdoor cafes on Stone Street.
But it never had anything like Printemps' nexus of high style and kitchen magic, which are surprising and delighting food-lovers, scene-makers and night owls.
Last Friday at 10 p.m. — two hours after the Printemps store closed — its flagship restaurant, Maison Passerelle, buzzed like a Wall Street Balthazar with couples dressed to kill.
7 The crisp-skinned ocean trout at Maison Passerelle is almost too pretty to eat.
Tamara Beckwith
The next afternoon, Salon Vert — a sexy, green-accented, second-floor raw bar/cafe — was so full, I had to wait for a seat at the bar.
Was this really happening at Broadway and Wall Street, a corner where the favorite dish historically was a street-cart hot dog?
Olivia Gracey, 31, a West Village publicist who's not involved with Printemps, was as surprised as me by Printemps culinary pleasures.
7 Gregory Gourdet, a finalist on seasons 12 and 17 of Bravo's 'Top Chef,' is overseeing all five restaurants at Printemps.
Tamara Beckwith
'We stumbled into Salon Vert as a reprieve from prowling the sunglasses and bags. I'm now obsessed,' she told me. 'I'd drink the sweet potato soup with a straw if they'd let me.'
Wealth advisor/consultant Marina Warner, 41, favors Cafe Jalu, a casual cafe next to Maison Passerelle.
'The people-watching is wild and hilarious. I didn't know so many fancy people were in FiDi with HUGE dogs,' she said, adding, 'The pain au chocolat is pretty insane when I need to eat my feelings in a good way.'
7 The beautiful Maison Passerelle has a vaguely tropical vibe.
Tamara Beckwith
All five eateries are run by Haitian-born chef Gregory Gourdet of Kent Hospitality Group — named for its beloved founder, the late chef James Kent.
Rather than offer a predictable department-store lineup of familiar standards, Gourdet, a finalist on Bravo's 'Top Chef,' bravely intertwines French cuisine with flavors of the French diaspora — the former colonies from Canada to the West Indies to Vietnam. There's no political statement behind it; the dishes are just meant to taste wonderful, which almost all did.
Maison Passerelle's 85 seats are the place to catch Gourdet's best work. The airy space designed by Laura Gonzalez (who did all the restaurants) has a vaguely tropical mood, with a marble mosaic floor, walnut walls, red jasper-topped tables, and plush, green-and-white fabric banquettes.
7 The standout dish is duck breast and confit glazed in cane syrup and bathed in tamarind jus.
Tamara Beckwith
Except for a misbegotten amuse bouche of mushroom broth with nuclear-hot Thai chilis that made three of us gag, just about everything was delicious. A starter of warm, richly herbed plantain bread and butter ($14) was sinfully filling.
The best dish was heritage duck breast and confit glazed in cane syrup and bathed in tamarind jus — a powerful, West African-inspired interplay of game-y, sweet and sweet-and-sour flavors. I almost didn't mind the $72 price, as it could be enough to serve two.
Spaghetti with Maine lobster ($60) arrived perfectly al dente. The tomato sauce was rich and plentiful, but the lobster was too chewy. I'd have gladly had half as much of the general shellfish portion if it were twice as tender.
7 Salon Vert, a raw bar and cafe, has been quite popular.
Tamara Beckwith
At Salon Verte, I enjoyed herbed, round focaccia with a crackling crust ($14) and shrimp Creole ($32) sparked with habanero, black pepper and horseradish.
Then there's the Red Room Bar, an appendage of the landmarked Red Room on the building's Wall Street side. The magnificent space was once open only to BNY Mellon executives until the bank moved out in 2015. It now serves as the store's shoe department with Italian-made Manolo Blahniks going for $1,375.
Sam Freeman, 33, an executive of Global Hotel Partnerships at American Express Travel & Lifestyle, likes the Red Bar's 'vibrant energy and unique ambiance, perfect for a meet-up or a drink after work and dinner.'
7 The light, fresh fare includes peekytoe crab remoulade.
Tamara Beckwith
He favors the Kafe Negroni ($21) spiked with Haitian coffee. For me, a crispy-crackling chicken sandwich ($24) on a potato bun heaped with pickled cabbage slaw and remoulade was all I needed to watch fashionistas smoothly descend a circular staircase to the ground floor with their pooches, huge and tiny, close at hand.
The stock market's wobbly, but I'm bullish on Wall Street's new eats.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
34 minutes ago
- Business Journals
A culture of compassion: How one Sacramento employer showed up when it mattered most
It's the phone call you never want to get: A grandparent slips away in the night. A parent unexpectedly passes. A loved one's illness takes a sudden turn. In these moments, everything stops, but the decisions don't. What now? Where do we begin? How will we afford this? When Angie, an HR director of a mid-sized Sacramento-based logistics company, received news that three of her team members - at three different sites - had each lost a loved one within just six days of each other, she worried about how she could help. One warehouse associate had lost his grandmother, a team lead at a Citrus Heights location was in need of cross-country travel arrangements to bury her father, and a senior dispatcher was quietly grieving the loss of his adult son, unsure how to even begin planning a service. Each employee had a different story but, all needed the same thing: support. A No-Cost Benefit With Real Impact: At Dignity Memorial®, we believe that no family should have to navigate grief alone or unprepared. That's why we created the Dignity Memorial Funeral Benefit Program, a no-cost offering now available to participating organizations and their employees/members. This unique benefit doesn't just support your team in their time of loss, it supports their families, too. expand What Our Program Includes: Employees/Members have access to exclusive services and savings at any Dignity Memorial provider nationwide, whether they choose to make arrangements in advance or at the time of need. This benefit extends to their spouse/domestic partner, and both the employee/member and their partners children, grandchildren, parents, grandparents, and even great-grandparents - whether they live locally or across the country. 10% savings on all funeral or cremation products and services [1] 10% savings on cemetery property, merchandise, and services [1] National transferability of prearranged services at no additional cost [2] 13 months of unlimited grief support via our 24-hour Compassion Helpline® [3] Bereavement travel assistance to help loved ones attend services, near or far Testimonies from the Team Carlos: 'My grandma raised me. Losing her was like losing a parent. I didn't know where to begin. Angie reminded me about the funeral benefit, and from the first call, the Dignity Memorial team took care of everything. They treated my family with respect and explained every option. It was a gift to not have to figure it all out alone, not to mention the space I had to grieve.' Janelle: 'When my dad died suddenly, I was panicked about the cost and the coordination, but the Dignity Memorial Bereavement Travel team got me a last-minute flight to Georgia, helped my sister book her flight too, and even found us a hotel near the cemetery. I had no idea my job offered that kind of support.' Marcus: 'My son died by suicide. I couldn't speak about it for weeks. But when I was ready, Dignity Memorial helped me plan a private, respectful memorial. And after, I used their 24-Hour Compassion Helpline. I didn't think grief counseling would help, but it did. It saved me.' A Workplace That Cares: Why Supporting Grieving Employees Matters In today's world, compassion is a competitive advantage, because grief doesn't stay at home, it follows your employees into meetings, deadlines, and performance reviews. The ability to offer practical support during loss isn't just kind, it's good business. Providing this benefit communicates a clear message: You care about your employees and their families beyond their day-to-day work. It tells them they matter, even in the most personal and vulnerable moments of life. When support shows up, practically and compassionately, it makes a lasting impact, and for employers, it's a meaningful way to enhance your benefits package, without adding cost to your bottom line. expand Learn More About Offering This Benefit When Grief knocks on someone's door, it matters who's standing with them on the front steps. What would it mean for your workplace culture to offer real, tangible support during those moments? Learn how your organization can offer the Dignity Memorial Funeral Benefit Program to your team. Serving families is our passion, our commitment and our expertise. Whether you're planning a funeral or cremation service for a loved one, or making your own arrangements in advance, meaningful life celebrations begin with Dignity Memorial's compassionate funeral and event planners. For Dignity Memorial providers, there is no greater honor than helping to remember a life lived. We are dedicated, local professionals committed to getting every detail right, every time. We do this by listening, caring and guiding each and every family who walks through our doors. It's why we've become a trusted part of the communities we serve and why families consistently give us 5-star ratings for exceptional care. [1] Where available by law. 10% savings is not available in all states nor does it apply to cash-advance items. Benefit only offered in states with Dignity affiliated cemeteries. On already discounted Dignity Memorial plans, consumer is entitled to the greater of the two discounts. [2] Certain restrictions apply.
Yahoo
2 hours ago
- Yahoo
AB Science announces the successful completion of a 2.55 million euros private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.55 MILLION PRIVATE PLACEMENT Paris, August 4, 2025, 8am CET AB Science S.A. (the 'Company' or 'AB Science', Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors (the 'Private Placement'). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the 'AMF'). In accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the 'Prospectus Regulation'), the Company file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the 'Information document'), copies of which will be available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company's cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 2.55 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 2,276,787 new ordinary shares of the Company (the 'New Shares'), each with one share warrant attached (a 'BSA' and, together with the New Share to which it is attached, an 'ABSA'), as part of a share capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 16th resolution of the Combined General Meeting of the Company's shareholders of June 30, 2025 (the 'General Meeting'), in accordance with Article L. 225-138 of the French commercial code (the 'Private Placement'). The issue of the ABSAs, representing approximately 3.34% of the Company's share capital, on a non-diluted basis, before completion of the Private Placement, and 3.23% of the Company's share capital, on a non-diluted basis, after completion of the Private Placement, was decided on August 1st, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated July 24, 2025, pursuant to the delegation of competence granted to it under the 16th resolution of the General Meeting . The issue price of one ABSA is EUR 1.12 (including share issue premium), representing a facial discount of 24.68% (i.e. EUR 0.3669) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ('Euronext Paris') over the three trading days preceding the setting of such issue price, i.e. August 1st and July 31 and 30, 2025 (the '3-day VWAP'). The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the exercise price of such BSA) represents a total 17.87% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 16th resolution. Terms and conditions of the BSA One BSA is attached to each New Share. One BSA entitles their holder to subscribe to one new ordinary share of the Company, at a price of EUR 1.71 per ordinary share. The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 2,276,787 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 3.89 million. The theoretical value of each BSA, assuming a volatility of 34.355%1 and based on closing price as of August 1st, 2025, is equal to EUR 0.3877 using Black & Scholes model. The BSAs will be immediately detached (détachés) from the New Shares upon issuance and are expected to be listed on Euronext Growth Paris ('Euronext Growth Paris') on or prior to August 11, 2025. Impact of the Private Placement on the Company's shareholding Following the issuance of the ABSAs, the Company's total share capital will be EUR 704,695.95 (or EUR 727,463.82 in the event of exercise of all BSAs). It will be comprised of 63,706,916 ordinary shares (or of 65,983,703 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares. To the Company's knowledge, immediately prior to completion of the Private Placement and after completion of the Private Placement, the breakdown of the Company's share capital is as follows: Shareholders Before the capital increase After the capital increase (before exercising the warrants) After the capital increase and exercise of the warrant Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) A. Moussy 7 345 396 10,77% 17,57% 7 345 396 10,42% 17,12% 7 345 396 10,10% 16,69% AMY SAS (3) 12 273 000 18,00% 14,20% 12 273 000 17,42% 13,84% 12 273 000 16,87% 13,49% Subtotal concert A. Moussy 19 618 396 28,77% 31,77% 19 618 396 27,84% 30,96% 19 618 396 26,97% 30,18% Other investors members of the concert 2 625 327 3,85% 5,97% 2 625 327 3,73% 5,82% 2 625 327 3,61% 5,67% Actions in the pact 1 123 902 1,65% 4,24% 1 123 902 1,59% 4,13% 1 123 902 1,54% 4,02% Actions outside the pact 1 501 425 2,20% 1,74% 1 501 425 2,13% 1,69% 1 501 425 2,06% 1,65% Total concert 22 243 723 32,62% 37,74% 22 243 723 31,56% 36,78% 22 243 723 30,58% 35,86% Other investors above 5% 6 888 610 10,10% 9,33% 6 888 610 9,78% 9,09% 6 888 610 9,47% 8,86% Other investors 39 060 475 57,28% 52,93% 41 337 262 58,66% 54,14% 43 614 049 59,95% 55,28% Total 68 192 808 100,00% 100,00% 70 469 595 100,00% 100,00% 72 746 382 100,00% 100,00% (1) All classes of shares are affected. The number of ordinary shares amounts to 61,430,129 before the Private Placement, 63,706,916 after the Private Placement (but before exercise of the BSAs), and 65,983,703 after the Private Placement and exercise of the BSAs.(2) The diluted basis takes into account the exercise of all instruments giving access to the capital, the definitive allocation of all free shares and the conversion of all preferred shares into ordinary shares (aiming for the highest theoretical dilution).(3) AMY SAS is a company controlled by A. Moussy. On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.97% on a non-diluted basis and 0.77% on a diluted basis. Admission to trading of the New Shares The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on August 7, 2025. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0010557264 – AB. Lock-up commitments The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Indicative timetable July 24, 2025 Decisions of the Board of Directors deciding the principle of the Private Placement. August 1st, 2025 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement). August 4, 2025 Publication of this press of the Information Document. August 7, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. August 7, 2025 Settlement-delivery of the ABSAs - Detachment of the BSA - Start of trading of the New Shares on Euronext Paris. August 11, 2025 Admission of the BSAs on Euronext Growth Paris. Risk factors AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company's website ( In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions. The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases. About AB8939 AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Disclaimer This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement. For additional information, please contact: AB Science Financial communication and public relationsinvestors@ 1Based on the volatility overt the last 12 months of the Euronext Next Biotech index. Attachment AB Science - August 2025 Press Release US VFSign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Atos recognized as Supplier Engagement Leader by CDP for the 5th time
Press Release Atos recognized as Supplier Engagement Leader by CDP for the 5th time Paris, France – July 30, 2025 – Atos has been recognized for the fifth time by the Carbon Disclosure Project (CDP) by being included in the prestigious Supplier Engagement Rating Leaderboard for its leadership in corporate supply chain engagement on climate change and environmental issues. Only the top companies which disclosed information for the full CDP Climate questionnaire secured a place on the CDP Supplier Engagement Leaderboard. Atos tackles its Scope 3 emissions, which represent the largest share (95.5%) of its GHG1 footprint, by working closely with its suppliers to assess and improve their sustainability performance. In 2024, 75%2 of Atos Group spend was made towards suppliers who had undergone a sustainability assessment. Atos suppliers can demonstrate their commitment to fight climate change by signing a dedicated contract clause with Atos whereby they are required to measure and report their emissions and commit to science-based climate targets. Atos also provides guidance and support to suppliers with lower sustainability maturity to help them initiate or improve their decarbonization journey. Marie de Scorbiac, Head of Investor Relations and CSR, Atos Group, said : 'Atos' inclusion on the 2024 CDP Supplier Engagement Leaderboard is a reward for its long-standing commitment to sustainable procurement and its rigorous, transparent reporting practices for customers, investors, and regulators. This recognition acknowledges the importance of our approach to engaging our suppliers and stakeholders.' Atos aims to continue engaging more suppliers on sustainability issues across its value chain and support them in their decarbonization journey to meet its GHG emission reduction targets and contribute to the fight against climate change. *** About Atos Group Atos Group is a global leader in digital transformation with c. 72,000 employees and annual revenue of c. € 10 billion, operating in 68 countries under two brands — Atos for services and Eviden for products. European number one in cybersecurity, cloud and high-performance computing, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos is a SE (Societas Europaea) and listed on Euronext Paris. The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space. Press contact Isabelle Grangé | | +33 (0) 6 64 56 74 88 1 GHG - GreenHouse Gas2 Atos 2024 Universal Registration Document Attachment PR-Atos recognized as Supplier Engagement Leader by CDP for the 5th time
